Page 251 - Haematologica May 2020
P. 251

Cardiac biomarkers in Mayo stage I amyloidosis
    Table 4. A review of the literature to outline previous studies and the previous prognostic thresholds of N-terminal pro b-type natriuretic peptide.
 Study details
Palladini G. et al.19 Dispenzieri A. et al.4 Kumar SK et al.20
NT-proBNP threshold
152 pmol/L=1,288 ng/L
332 ng/L
332 ng/L
Survival
7.6 per 100 person-years (95% CI: 3.6-15.7)
and 72.2 per 100 person-years (95% CI: 54.2-86.1)
<332 pg/mL survival 20 months
>332 pg/mL 5.8 months
Median OS from diagnosis for patients NT proBNP <332 ng/L
was 4.0 years versus 2.4 years if either NT-proBNP was >332 ng/L
or cTnT >0.035 g/L.
5-year survival 98% versus 88% for those above and below respectively
NT-ProBNP ≥ 1,800 pg/mL was 10.5 months, compared with median not reached for those with NT-ProBNP <1,800 pg/mL
    Wechalekar AD et al.13
Kumar S et al.25
NT-proBNP: N-terminal pro b-type natriuretic peptide; CI: confidence interval; OS: overall survival.
NT-proBNP <15
 pMol/L=127 ng/L 1,800 pg/mL=1,800 ng/L
   AB
CD
 Figure 3. Cardiac magnetic resonance image of a patient with no evidence of cardiac amyloidosis by echocardiogram and NT-BNP <332 ng/L showing character- istic features of cardiac involvement. (A) Four-chamber steady state free precession (SSFP) cine (top right panel). (B) Corresponding native T1 map (top left panel) with an elevated value of 1209 m. (C) Corresponding phase sensitive inversion recovery late gadolinium enhancement (PSIR LGE) image showing subendocardial LGE (bottom right panel).(D) Corresponding extracellular volume (ECV) map with an elevated value of 0.47 (bottom left panel).
  haematologica | 2020; 105(5)
1411
   






































































   249   250   251   252   253